REGENXBIO Inc.
RGNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $382,705 | $785,025 | $978,687 | $1,387,723 |
| - Cash | $57,526 | $34,522 | $96,952 | $345,209 |
| + Debt | $141,720 | $89,290 | $94,799 | $86,681 |
| Enterprise Value | $466,899 | $839,793 | $976,534 | $1,129,195 |
| Revenue | $83,328 | $90,242 | $112,724 | $470,347 |
| % Growth | -7.7% | -19.9% | -76% | – |
| Gross Profit | $49,761 | $53,029 | $58,179 | $418,514 |
| % Margin | 59.7% | 58.8% | 51.6% | 89% |
| EBITDA | -$198,228 | -$239,464 | -$244,242 | $169,544 |
| % Margin | -237.9% | -265.4% | -216.7% | 36% |
| Net Income | -$227,102 | -$263,494 | -$280,321 | $127,840 |
| % Margin | -272.5% | -292% | -248.7% | 27.2% |
| EPS Diluted | -4.59 | -6.02 | -6.5 | 2.91 |
| % Growth | 23.8% | 7.4% | -323.4% | – |
| Operating Cash Flow | -$173,125 | -$218,407 | -$207,488 | $218,875 |
| Capital Expenditures | -$2,436 | -$9,960 | -$30,724 | -$84,175 |
| Free Cash Flow | -$175,561 | -$228,367 | -$238,212 | $134,700 |